Close
Blog & Resources Camargo Blog February 5th, 2009

2008 505(b)(2) Approvals

For the first time, FDA’s new drug division has approved more 505(b)(2) drugs than those submitted via 505(b)(1). In 2006 and 2007, the percentage of 505(b)(2) drug approvals went from 20 to 43%, respectively. The FDA publishes a list of drugs approved each year and this list for approvals through November, 2008 has a column “505(b)(2) Flag”. We have found this column to be unreliable – several rows of (b)(1)’s are checked with a (b)(2) flag. The following table was compiled by reviewing the approval documents for all new drugs approved in calendar 2008; these documents can be found by following the hyperlink for each drug product.

Established Name****Proprietary Name****Applicant****Approval

**New Molecular Entities**
Bendamustine HydrochlorideTreandaCephalon20-Mar-08
Fospropofol DisodiumLusedraEisai Medical Research12-Dec-08
Iobenguane I 123 InjectionAdreViewGE Healthcare19-Sep-08
**New Esters, Salts, or Other Noncovalent Derivatives**
Bupropion HydrobromideAplenzinBiovail Labs23-Apr-08
Fenofibric AcidTrilipixAbbott15-Dec-08
Granisetron Transdermal SystemSancusoStrakan12-Sep-08
**New Formulations**
Abacavir Sulfate; LamivudineAbacavir SulfateAurobindo Pharma Ltd19-Dec-08
Amiodarone HydrochlorideNexteronePrism Pharma24-Dec-08
AmoxicillinMoxatagMiddlebrook23-Jan-08
Cefepime InjectionCefepime InjectionBaxter05-Aug-08
EfavirenzEfavirenzAurobindo Pharma Ltd12-Dec-08
Fluorescein InjectionAk-FluorAkorn08-Aug-08
Lidocaine HydrochlorideAktenAkorn07-Oct-08
MesalamineAprisoSalix31-Oct-08
Phentolamine MesylateOraverseNovalar09-May-08
Prednisolone AcetateFlo-PredTaro17-Jan-08
Triamcinolone AcetonideTrivarisAllergan16-Jun-08
Valproic AcidStavzorBanner29-Jul-08
Venlafaxine HydrochlorideVenlafaxine HydrochlorideOsmotica20-May-08
Zolpidem TartrateZolpimistNovadel19-Dec-08
**New Combinations**
Adapalene; Benzoyl PeroxideEpiduoGalderma Labs08-Dec-08
Niacin/SimvastatinSimcorAbbott15-Feb-08
Repaglinide/Metformin HydrochloridePrandiMetNovo Nordisk23-Jun-08
Sumatriptan; Naproxen SodiumTreximetPozen15-Apr-08
**New Formulation and New Combination**
Methyl Salicylate & MentholSalonpasHisamitsu20-Feb-08
**Drug Already Marketed, but Without an Approved NDA**
Morphine SulfateMorphine SulfateRoxane17-Mar-08 (2 NDAs)
**Tentative Approvals**
Docetaxel InjectionDocetaxel InjectionHospira Inc11-Aug-08
Pantoprazole SodiumPantoprazole SodiumTeva Parenteral20-Oct-08

Based on the number of NDA’s that Camargo is compiling for just our clients, we expect 505(b)(2) to dominate the approval list in 2009. Looking at the number of IND’s we are filing, we expect that by 2012, the percentage of 505(b)(2) approvals will be greater than 90%.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights